Literature DB >> 19886856

Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress.

Hiroshi Yamanari1, Kazufumi Nakamura, Daiji Miura, Shuichi Yamanari, Tohru Ohe.   

Abstract

The side effects of thiazide-type diuretics include metabolic abnormality and increased oxidative stress, which might cause endothelial dysfunction despite blood pressure reduction. In hypertensive patients with heart failure, treatment with an aldosterone antagonist resulted in improvements in endothelial function and significant blood pressure reduction. The purpose of the present study was to evaluate the differences between spironolactone and chlorthalidone in hypertensive elderly patients treated with calcium antagonists and angiotensin II receptor blockers. Fourteen uncontrolled hypertensive patients treated with amlodipine and candesartan were included in this study. The study was an open-label randomized crossover comparison of 16 weeks treatment with spironolactone against chlorthalidone added to amlodipine and candesartan. Blood pressure significantly decreased in patients treated with both spironolactone and chlorthalidone. Chlorthalidone reduced flow mediated dilation significantly compared to the baseline condition and spironolactone. Serum high sensitively C-reactive protein and uric acid increased significantly in chlorthalidone-treated patients compared to spironolactone treated patients. We conclude that spironolactone may be a more useful add-on therapy than chlorthalidone in hypertensive patients inadequately controlled on candesartan and amlodipine, because spironolactone preserves endothelial function and reduces inflammation compared to chlorthalidone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19886856     DOI: 10.3109/10641960902929438

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  8 in total

1.  Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.

Authors:  Kristen L Nowak; Berenice Gitomer; Heather Farmer-Bailey; Wei Wang; Mikaela Malaczewski; Jelena Klawitter; Zhiying You; Diana George; Nayana Patel; Anna Jovanovich; Michel Chonchol
Journal:  Am J Kidney Dis       Date:  2019-02-23       Impact factor: 8.860

Review 2.  Chlorthalidone: mechanisms of action and effect on cardiovascular events.

Authors:  George C Roush; Venkata Buddharaju; Michael E Ernst; Theodore R Holford
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

Review 3.  Which diuretic is the preferred agent for treating essential hypertension: hydrochlorothiazide or chlorthalidone?

Authors:  F Wilford Germino
Journal:  Curr Cardiol Rep       Date:  2012-12       Impact factor: 2.931

Review 4.  Hypertension: a new treatment for an old disease? Targeting the immune system.

Authors:  Gisele Facholi Bomfim; Stefany Bruno Assis Cau; Alexandre Santos Bruno; Aline Garcia Fedoce; Fernando S Carneiro
Journal:  Br J Pharmacol       Date:  2018-07-31       Impact factor: 8.739

Review 5.  Role of endothelin receptor A and NADPH oxidase in vascular abnormalities.

Authors:  De-Zai Dai; Yin Dai
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

6.  The effect of antihypertensive drugs on endothelial function as assessed by flow-mediated vasodilation in hypertensive patients.

Authors:  Michiaki Miyamoto; Kazuhiko Kotani; Shun Ishibashi; Nobuyuki Taniguchi
Journal:  Int J Vasc Med       Date:  2012-02-29

Review 7.  Does Excess Tissue Sodium Storage Regulate Blood Pressure?

Authors:  Giacomo Rossitto; Christian Delles
Journal:  Curr Hypertens Rep       Date:  2022-02-22       Impact factor: 4.592

Review 8.  Comparative Efficacy of Antihypertensive Agents in Flow-Mediated Vasodilation of Patients with Hypertension: Network Meta-Analysis of Randomized Controlled Trial.

Authors:  Hong Ding; Shu Liu; Ke-Xin Zhao; Jie Pu; Ya-Fei Xie; Xiao-Wei Zhang
Journal:  Int J Hypertens       Date:  2022-04-30       Impact factor: 2.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.